
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
P2Y5 CRISPR/Cas9 KO Plasmid (m) | sc-426423 | 20 µg | $397.00 |
Lpar6 encodes the P2Y5 receptor, a lysophosphatidic acid (LPA)-responsive G protein–coupled receptor implicated in lipid mediator sensing and downstream signaling through pathways that regulate cytoskeletal dynamics, cell polarity, and differentiation. In mouse tissues, P2Y5 activity links extracellular LPA to intracellular second-messenger networks that can influence MAPK and Rho-family signaling outputs, shaping processes such as epithelial organization and hair follicle biology. Genetic and functional studies associate LPAR6/P2Y5 with hair growth phenotypes and ectodermal development, and altered LPA receptor signaling is broadly relevant to inflammatory and fibrotic microenvironments. As a result, Lpar6 provides a useful entry point for dissecting GPCR-driven lipid signaling and its effects on cell behavior in physiologically relevant models.
P2Y5 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Lpar6 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Lpar6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Lpar6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish P2Y5 protein expression.
This CRISPR knockout system enables efficient generation of Lpar6-deficient cell models for investigation of P2Y5 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.